CTRI/2018/05/013727招募中未知
Advancing Cancer-care through CANScriptTMEnabled Personalized Treatment(ACCEPT): A non-randomized, investigator initiated, observational trial to measure predictive power of CANScriptTM for chemotherapeutics and targeted therapy in patients with newly diagnosed, locally advanced head & neck cancer and refractory / relapsed triple negative breast cancer
试验速览
- 阶段
- 未知
- 状态
- 招募中
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
入选标准
- •1.Patients with locally advanced H&N Ca requiring neo-adjuvant therapy, aged 18-75 are eligible for the ACCEPT-H&N trial.
- •2.Patients from whom at least 100-200 mm3 non-necrotic tumor can be obtained by biopsy or surgery.
- •3.ECOG Performance Status of 0 â?? 1
排除标准
- •1.Any other concurrent disease or illness, which in the judgment of the investigator
- •would make the subject inappropriate for entry into the study
研究者
相似试验
尚未招募
不适用
To determine the effectiveness of CANScript, the anti-cancer drug sensitivity test in determining the most optimal drug combination for a cancer patientCTRI/2015/06/005943Mitra Biotech Pvt Ltd195
招募中
2 期
Improving public cancer care by implementing precision medicine in NorwayCancer2023-507894-16-00Oslo University Hospital HF1,000
已完成
2 期
Towards patient tailored cancer treatment supported by molecular imaging IMPACT: IMaging PAtients for Cancer drug selecTion - Metastatic Breast Cancermetastatic breast cancermammacarcinoma10006291NL-OMON41527niversitair Medisch Centrum Groningen200
进行中（未招募）
不适用
Imaging patients for cancer drug selection - metastatic breast cancerMetastatic Breast CancerEUCTR2013-000551-41-NLniversity Medical Center Groningen
招募中
不适用
TeleCaRe: Expanding delivery of Cancer Rehabilitation via telehealthCancer - Any cancercancerACTRN12621001417875Eastern Health116